Mabpharm (HKSE:02181) ROCE %: 2.05% (As of Dec. 2025)


HKSE:02181 Mabpharm Ltd HKSE:02181
38 GF Score
Price HK$0.40
GF Value HK$1.96
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Mabpharm ROCE %?

Mabpharm HKSE:02181 38 ROCE % is 2.05% as of Dec. 2025. GuruFocus rates HKSE:02181 with a GF Score™ of 38/100 and a GF Value™ of HK$1.96 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mabpharm's annualized ROCE % for the quarter that ended in Dec. 2025 was 2.05%.

Mabpharm  (HKSE:02181) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mabpharm ROCE % Related Terms

Mabpharm ROCE % Historical Data

* Premium members only.

The historical data trend for Mabpharm's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabpharm ROCE % Chart

Mabpharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -36.29 -27.93 -27.31 -16.30 2.30

Mabpharm Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.49 -26.12 -7.26 2.43 2.05
HKSE:02181
38GF Score
Mabpharm Ltd HKSE:02181
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabpharm ROCE % Calculation

Mabpharm's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=16.537/( ( (1084.988 - 333.247) + (1274.256 - 589.972) )/ 2 )
=16.537/( (751.741+684.284)/ 2 )
=16.537/718.0125
=2.30 %

Mabpharm's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=14.684/( ( (1167.219 - 418.65) + (1274.256 - 589.972) )/ 2 )
=14.684/( ( 748.569 + 684.284 )/ 2 )
=14.684/716.4265
=2.05 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 2.05% mean?
Mabpharm (HKSE:02181) has a ROCE % of 2.05% as of Dec. 2025.
Is Mabpharm's ROCE % too high?
Mabpharm's current ROCE % is 2.05%. Overall, Mabpharm has a GF Score™ of 38/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mabpharm's ROCE % compare to VRTX and REGN?
Mabpharm's ROCE % of 2.05% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Mabpharm's current ROCE % is 2.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabpharm stock overvalued right now?
Based on GuruFocus' analysis, Mabpharm (HKSE:02181) is currently considered Possible Value Trap. The stock's GF Value™ is HK$1.96, compared to a current price of HK$0.40 — trading 79.8% below its estimated fair value. The current ROCE % is 2.05%. Mabpharm's overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Mabpharm (HKSE:02181), the current ROCE % is 2.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabpharm (HKSE:02181) Overvalued in 2026?

Based on GuruFocus' analysis, Mabpharm stock appears to be undervalued. The current stock price of HK$0.40 is trading 79.8% below its estimated GF Value™ of HK$1.96. GuruFocus considers Mabpharm to be Possible Value Trap.

Key valuation signals for HKSE:02181:

  • ROCE %: 2.05%
  • GF Value™: HK$1.96 vs. price of HK$0.40 (79.8% below fair value)
  • GF Score™: 38/100 with 7 warning signs

No single metric tells the full story. See the HKSE:02181 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabpharm Business Description

Address Lujia Road East, Koutai Road West, Block G79, China Medical City, Taizhou, CHN, 225300
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab). Company operates in Chinese Mainland and Others.
38GF Score

Get the complete analysis for HKSE:02181

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.40
Price
HK$1.96
GF Value